This PubMed record reports the final survival analysis of the ANDROMEDA clinical trial assessing daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (VCD) for patients with newly diagnosed immunoglobulin light‑chain (AL) amyloidosis. The article appears in Blood (2026 Aug 27;148(9):1097–1107) and carries DOI 10.1182/blood.2025032099.
The PubMed landing page supplied as the source contains the citation, author list, collaborating investigator group name (ANDROMEDA Trial Investigators), links to full‑text providers, and institutional affiliations. The record identifies the work as a clinical trial and labels this specific manuscript as the final survival analysis, indicating the manuscript presents survival outcomes after a period of follow‑up.
The published paper lists a large, international authorship that includes named investigators and the corporate author group ANDROMEDA Trial Investigators. Institutional affiliations span specialized amyloidosis centers, university hematology departments, and multiple international hospitals and research centers across Europe, North America and Asia. Several contributors are affiliated with Johnson & Johnson, and the PubMed record includes named industry collaborators.
From the citation and title, the primary focus is the survival impact of adding daratumumab to a standard backbone of bortezomib‑cyclophosphamide‑dexamethasone in newly diagnosed AL amyloidosis. The ANDROMEDA study has been reported previously in earlier publications and abstracts; this record identifies the present article as the final survival analysis, which typically reports long‑term endpoints such as overall survival and possibly progression‑free survival or organ response durability.
The PubMed excerpt confirms this is a clinical trial comparing a regimen containing daratumumab plus bortezomib‑cyclophosphamide‑dexamethasone. Beyond the treatment combination and the designation of a final survival analysis, the provided source text does not include randomized design details, eligibility criteria, sample size, dosing schedules, duration of therapy, or follow‑up intervals. The presence of multiple international sites and the ANDROMEDA investigator group suggests a multicenter trial, but the excerpt does not report operational specifics.
The record identifies the manuscript as the final survival analysis; however, the supplied PubMed page excerpt does not provide numerical results, survival curves, hazard ratios, confidence intervals, p values, or tabulated outcomes. No safety or adverse event data, subgroup analyses, or organ‑response outcomes are contained in the excerpt provided here.
The excerpt on the PubMed record provides citation metadata, author and affiliation lists, and links to full text, but does not include the trial's methods, endpoints, statistical plan, or outcome data. Specifically not reported in this source excerpt are:
Because these items are not present in the provided PubMed content, they cannot be restated or interpreted here.
The publication of a final survival analysis in a high‑impact hematology journal indicates that the ANDROMEDA investigators considered long‑term survival outcomes important for assessing the regimen’s clinical value in AL amyloidosis. The combination of an anti‑CD38 monoclonal antibody (daratumumab) with a proteasome inhibitor‑based backbone (bortezomib) plus alkylator and steroid (cyclophosphamide, dexamethasone) reflects a strategy to deepen hematologic responses and potentially improve organ and survival outcomes in this disease.
However, the present source excerpt does not permit evaluation of whether survival was improved, whether safety signals emerged, or how results should change practice. Any clinical interpretation must therefore be deferred until the full text is consulted.
The PubMed record includes links to full‑text providers (Blood via Silverchair and Elsevier). For clinicians, researchers, or guideline panels seeking to apply these findings, accessing the full article is required to review methods, full results, subgroup analyses, adverse events and authors’ conclusions. The PubMed page and DOI (10.1182/blood.2025032099) should be used to retrieve the complete manuscript.
If you would like, I can fetch or summarize the full‑text report (if accessible) or extract key numerical outcomes and safety data from the published article; please confirm and I will proceed to obtain the full text and provide a data‑focused summary.